Managing GIST in the imatinib era: optimization of adjuvant therapy

References

• Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152(5):1259-69
   PubMed Web of Science ®Google Scholar
• Kleinbaum EP, Lazar AJ, Tamborini E, et al. Clinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumor. Int J Cancer 2008;122(3):711-18
   PubMedGoogle Scholar
• Erlandson RA, Klimstra DS, Woodruff JM. Subclassification of gastrointestinal stromal tumors based on evaluation by electron microscopy and immunohistochemistry. Ultrastruct Pathol 1996;20(4):373-93
   PubMed Web of Science ®Google Scholar
• Nilsson B, Sjolund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer 2007;96(11):1656-8
   PubMed Web of Science ®Google Scholar
• Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005;117(2):289-93
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130(10):1466-78
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23(2):70-83
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279(5350):577-80
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61(22):8118-21
   PubMed Web of Science ®Google Scholar
• Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20(18):3898-905
   PubMedGoogle Scholar
• Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125(3):660-7
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299(5607):708-10
   PubMed Web of Science ®Google Scholar
• Agaram NP, Wong GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer 2008;47(10):853-9
   PubMed Web of Science ®Google Scholar
• Belinsky MG, Rink L, Flieder DB, et al. Overexpression of insulin-like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild-type SDHB-negative gastrointestinal stromal tumors. Genes Chromosomes Cancer 2013;52(2):214-24
   PubMed Web of Science ®Google Scholar
• Gill AJ, Chou A, Vilain R, et al. Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types. Am J Surg Pathol 2010;34(5):636-44
   PubMedGoogle Scholar
• Janeway KA, Kim SY, Lodish M, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011;108(1):314-18
   PubMed Web of Science ®Google Scholar
• Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3(11):655-64
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347(7):472-80
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358(9291):1421-3
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373(9669):1097-104
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Ballman KV, Antonescu CR, et al. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg 2013;258(3):422-9
   PubMed Web of Science ®Google Scholar
• Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992;69(6):1334-41
   PubMed Web of Science ®Google Scholar
• DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231(1):51-8
   PubMed Web of Science ®Google Scholar
• Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006;244(2):176-84
   PubMedGoogle Scholar
• Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33(5):459-65
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29(1):52-68
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network® (NCCN). NCCN clinical practice guidelines in Oncology^TM: soft tissue sarcoma. 2014; Version 2. 2014
   Google Scholar
• National Comprehensive Cancer Network® (NCCN). NCCN clinical practice guidelines in Oncology^TM: soft tissue sarcoma. 2013; Version 1. 2013
   Google Scholar
• The American Society of Clinical Oncology (ASCO). Available from: http://meetinglibrary.asco.org/abstracts [Last accessed 1 January 2014]
   Google Scholar
• Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008;39(10):1411-19
   PubMed Web of Science ®Google Scholar
• Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10(11):1045-52
   PubMed Web of Science ®Google Scholar
• Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. Int J Clin Exp Pathol 2010;3(5):461-71
   PubMed Web of Science ®Google Scholar
• Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol 2014;32(15):1563-70
   PubMed Web of Science ®Google Scholar
• Muguruma K, Kurokawa Y, Tsujinaka T, et al. Randomized phase II study of 6 versus 12 months of adjuvant imatinib for patients with intermediate- or high-risk GIST. J Clin Oncol 2012;30(Suppl 34):abstract 9
   Google Scholar
• Li J, Gong JF, Wu AW, Shen L. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011;37(4):319-24
   PubMedGoogle Scholar
• Kang YK, Kang BW, Im SA, et al. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation. Cancer Chemother Pharmacol 2013;71(1):43-51
   PubMedGoogle Scholar
• McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009;16(4):910-19
   PubMed Web of Science ®Google Scholar
• Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99(1):42-7
   PubMed Web of Science ®Google Scholar
• Wang D, Zhang Q, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2012;19(4):1074-80
   PubMed Web of Science ®Google Scholar
• Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007;25(9):1107-13
   PubMed Web of Science ®Google Scholar
• Patrikidou A, Chabaud S, Ray-Coquard I, et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol 2013;24(4):1087-93
   PubMed Web of Science ®Google Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307(12):1265-72
   PubMed Web of Science ®Google Scholar
• Espat J, Maki RG, Raut CP, et al. Demonstration of gender-specific variability in a pharmacokinetic (PK) analysis of the PERSIST-5 trial of adjuvant imatinib (IM) for patients with primary gastrointestinal stromal tumor (GIST) at significant risk of recurrence. J Clin Oncol 2013;31(Suppl):abstract 10538
   Google Scholar
• US National Institutes of Health. Safety and efficacy evaluation of two year imatinib treatment in adjuvant gastrointestinal stromal tumor (GIST) (INV555). Available from: http://clinicaltrials.gov/show/NCT01172548 [Last accessed 14 May 2014]
   Google Scholar
• Casali PG, Le Cesne A, Velasco AP, et al. Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): the EORTC/AGITG/FSG/GEIS/ISG randomized controlled Phase III trial. J Clin Oncol 2013;31(Suppl):abstract 10500
   Google Scholar
• Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012;13(3):265-74
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21(23):4342-9
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40(5):689-95
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26(33):5360-7
   PubMed Web of Science ®Google Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42(8):1093-103
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010;28(7):1247-53
   PubMed Web of Science ®Google Scholar
• Rutkowski P, Bylina E, Wozniak A, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011;37(10):890-6
   PubMed Web of Science ®Google Scholar
• Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003;98(12):2693-9
   PubMed Web of Science ®Google Scholar
• Beckman M. More clinical cancer treatments judged by progression-free rather than overall survival. J Natl Cancer Inst 2007;99(14):1068-9
   PubMedGoogle Scholar
• Lee JL, Ryu MH, Chang HM, et al. Clinical outcome in gastrointestinal stromal tumor patients who interrupted imatinib after achieving stable disease or better response. Jpn J Clin Oncol 2006;36(11):704-11
   PubMedGoogle Scholar
• Conley AP, Guerin A, Sasane M, et al. Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach. J Gastrointest Cancer 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Otomi Y, Otsuka H, Morita N, et al. Relationship between FDG uptake and the pathological risk category in gastrointestinal stromal tumors. J Med Invest 2010;57(3-4):270-4
   PubMedGoogle Scholar
• Eisenberg BL, Pipas JM. Gastrointestinal stromal tumor–background, pathology, treatment. Hematol Oncol Clin North Am 2012;26(6):1239-59
   PubMedGoogle Scholar
• Zhao WY, Xu J, Wang M, et al. Prognostic value of Ki67 index in gastrointestinal stromal tumors. Int J Clin Exp Pathol 2014;7(5):2298-304
   PubMedGoogle Scholar
• Dumont AG, Yang Y, Reynoso D, et al. Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors. Carcinogenesis 2012;33(9):1674-83
   PubMedGoogle Scholar
• Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011;11(12):865-78
   PubMed Web of Science ®Google Scholar
• Zhan WH; China Gastrointestinal Cooperative Group. Efficacy and safety of adjuvant post-surgical therapy with imatinib in patients with high risk of relapsing. J Clin Oncol 2007;25(Suppl):abstract 10045
   Google Scholar
• US National Institutes of Health. Five year adjuvant imatinib mesylate (Gleevec®) in gastrointestinal stromal tumor (GIST). Available from: http://clinicaltrials.gov/show/NCT00867113 [Last accessed 27 April 2014]
   Google Scholar
• Yalcin S, Buyukberber S, Yilmaz U, et al. Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): efficacy and safety at one year. J Clin Oncol 2012;30(Suppl):abstract e20514
   Google Scholar
• US National Institutes of Health. Imatinib mesylate or observation only in treating patients who have undergone surgery for localized gastrointestinal stromal tumor (EORTC62024). Available from: http://clinicaltrials.gov/show/NCT00103168 [Last accessed 28 October 2013]
   Google Scholar
• International Union Against Cancer (UICC), Sobin L, Gospodarowicz M, Wittekind C. TNM classification of malignant tumours. 7th edition. Wiley; New York, NY, USA: 2009
   Google Scholar
• International Union Against Cancer (UICC), Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th edition. Wiley; New York, NY, USA: 2002
   Google Scholar